POZEN announces receipt of $20 million milestone payment from AstraZeneca
POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the US Food and Drug Administration approval of VIMOVO™ delayed-release tablets on April 30 th .
Chapel Hill drug company Pozen reported this morning that it posted a $13.3 million profit in the second-quarter -- reversing its loss of a year ago -- thanks to a $20 million milestone payment from partner GlaxoSmithKline.